92042-45-0 Usage
Chemical structure
A derivative of cyclopentanecarboxylic acid with a sulfonylamino group attached to the cyclopentane ring and a 4-methylphenyl group attached to the sulfonylamino group.
Molecular weight
Approximately 277.35 g/mol (calculated from the molecular formula)
Functional groups
a. Carboxylic acid group (-COOH)
b. Sulfonylamino group (-SO2NH2)
c. Aromatic ring (4-methylphenyl)
Potential applications
a. Pharmaceutical applications due to its ability to interact with biological systems
b. Influence on enzymatic activity or receptor binding
Further research needed
a. Characterization of biological and chemical properties
b. Determination of potential uses and effects
Solubility
Not specified in the material provided, but may depend on the polarity of the molecule and the solvent used.
Stability
Not specified in the material provided, but may be influenced by factors such as temperature, pH, and exposure to light or air.
Reactivity
Not specified in the material provided, but the presence of functional groups suggests potential reactivity with other molecules, such as nucleophiles or electrophiles.
Synthesis
Not specified in the material provided, but the synthesis of this compound would likely involve the formation of the sulfonylamino group and the attachment of the 4-methylphenyl group to the cyclopentanecarboxylic acid core.
Check Digit Verification of cas no
The CAS Registry Mumber 92042-45-0 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 9,2,0,4 and 2 respectively; the second part has 2 digits, 4 and 5 respectively.
Calculate Digit Verification of CAS Registry Number 92042-45:
(7*9)+(6*2)+(5*0)+(4*4)+(3*2)+(2*4)+(1*5)=110
110 % 10 = 0
So 92042-45-0 is a valid CAS Registry Number.
92042-45-0Relevant articles and documents
Compounds which inhibit leukocyte adhesion mediated by VLA-4
-
Page/Page column 53; 50, (2008/06/13)
Disclosed are compounds which bind VLA-4. Certain of these compounds also inhibit leukocyte adhesion and, in particular, leukocyte adhesion mediated by VLA-4. Such compounds are useful in the treatment of inflammatory diseases in a mammalian patient, e.g.
